Halda Therapeutics
Kyle Bassoli has a diverse work experience spanning over 20 years. Kyle is currently working at Halda Therapeutics as a Research Investigator, where they began in February 2023 after serving as a Senior Research Scientist from May 2022 to February 2023. Prior to that, they worked at Valo as a Scientist I from April 2022 to May 2022 and as a Principal Associate Scientist from March 2020 to April 2022. Before joining Valo, Kyle worked at FORMA Therapeutics, Inc. as a Principal Research Associate from March 2018 to March 2020. Their responsibilities included providing analytical support to Process Chemistry and CMC teams, HPLC method development, technical document preparation, and purification of ultra-pure material. Kyle's experience at FORMA Therapeutics, Inc. also includes roles as a Senior Research Associate from January 2014 to January 2018, a Research Associate from August 2010 to January 2014, and an Assistant Research Associate from January 2009 to August 2010. Kyle started their career at Cara Therapeutics, Inc. as an Assistant Scientist, where they managed the Compound Repository, chemical reagent inventory, and helped develop in-house thermodynamic solubility assays. Prior to that, Kyle worked at Bayer Pharmaceuticals as an Associate Research Scientist, handling compound dispensing, managing project schedules, and coordinating shipments. Kyle began their career as a Student Horticultural Technician at the University of Connecticut, where they gained experience in greenhouse maintenance, plant propagation, and greenhouse environmental control systems.
Kyle Bassoli attended the University of Connecticut from 2001 to 2005. During this time, they pursued a Bachelor of Science (BS) degree in Cell/Cellular and Molecular Biology.
Halda Therapeutics
1 followers
Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines. Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.